- NeoGenomics (NEO, Financial) to present the PanTracer LBx validation study at the AACR Annual Meeting 2025 in Chicago.
- PanTracer LBx is an NGS liquid biopsy panel for comprehensive pan-solid tumor profiling.
- The company has launched an Evaluation Assessment Program for select physicians to use PanTracer LBx before full commercial availability.
NeoGenomics, Inc. (NEO), a leader in oncology testing services, is set to present the analytical validation of its PanTracer LBxâ„¢ assay at the American Association for Cancer Research (AACR) Annual Meeting 2025. The meeting will take place in Chicago from April 25-30, where the study will be showcased on April 29 from 9 AM - 12 PM CT.
The PanTracer LBx is a next-generation sequencing (NGS) liquid biopsy panel developed for comprehensive profiling of pan-solid tumors. It is specifically designed to analyze circulating tumor DNA and identify key genomic alterations in patients with advanced-stage solid tumors. This assay is particularly beneficial when tumor tissue is unavailable or insufficient, a common obstacle in oncology care.
The validation study demonstrated PanTracer LBx's high performance in identifying crucial biomarkers, including microsatellite instability (MSI) and tumor mutational burden (TMB), across various cancer types. These results highlight its potential to guide therapy selection and broaden access to precision oncology treatments.
To facilitate the rollout of PanTracer LBx, NeoGenomics has initiated an Evaluation Assessment Program. This program will allow select physicians to utilize the assay before its full commercial release, aiming to refine logistics, reporting, and customer support processes.
NeoGenomics is also set to present five additional posters at the meeting, covering topics such as tumor biology and genomic co-occurrence. The company's presence at AACR underscores its dedication to advancing oncology diagnostics and developing solutions that benefit both patients and providers.
